Champions Oncology, Inc. — Form 10-Q Summary
Business context and reporting period
The filing covers the three months ended July 31, 2017, compared with the three months ended July 31, 2016. Champions Oncology develops and sells oncology technology and services using its TumorGraft platform. Its two businesses are Personalized Oncology Solutions (POS), serving physicians and patients, and Translational Oncology Solutions (TOS), serving pharmaceutical and biotechnology companies. Management says future growth efforts will focus on TOS; POS will not be a growth focus.
Financial performance and position
| Metric | Three months ended July 31, 2017 | Prior-year comparable |
|---|---|---|
| Revenue | $5.033 million | $3.670 million |
| Operating loss | $619,000 | $2.523 million |
| Net loss | $674,000 | $2.546 million |
| Net loss per share, basic and diluted | $0.06 | $0.26 |
| Net cash used in operating activities | $1.948 million | $2.439 million |
| Capital expenditures | $910,000 | $17,000 |
- Revenue and mix: Revenue increased 37.1%. TOS revenue rose 45.4% to $4.594 million, attributed to growth in the number and size of studies. POS revenue fell 14.1% to $439,000.
- Margins: Reported gross margins were 50.9% for TOS, up from 35.1%, and 11.8% for POS, up from 7.2%. Management cited higher TOS revenue against fixed lab costs and cost management; POS improvement reflected a greater contribution from higher-margin sequencing revenue and lab cost management.
- Expenses: Total costs and operating expenses declined 8.7% to $5.652 million. Research and development fell 7.7% to $1.118 million, sales and marketing fell 26.2% to $683,000, and general and administrative fell 21.2% to $1.209 million. Management attributed expense reductions in part to lower stock-based compensation.
- Balance sheet at July 31: Cash and cash equivalents were $430,000, versus $3.295 million at April 30. Current assets were $3.457 million and current liabilities were $6.020 million, implying negative working capital of approximately $2.6 million. Total liabilities were $6.177 million; stockholders’ equity was $290,000. Deferred revenue was $3.737 million.
- Debt and liquidity: The filing reports no off-balance-sheet debt or similar obligations. A laboratory-equipment capital lease had a $58,000 present value of remaining payments at July 31, 2017. Operating cash outflow and lab investment drove a $2.865 million quarterly decline in cash.
Changes, outlook, risks, and unusual items
- Operating loss narrowed to $619,000 from $2.523 million, and net loss narrowed to $674,000 from $2.546 million. Management also cited fiscal 2017 revenue growth of 38% and $3.6 million reductions in both net loss and cash use year over year.
- The company invested $910,000 in equipment for a new Rockville, Maryland lab and incurred approximately $100,000 in non-capitalized, non-recurring setup costs, which management said are not expected to recur. The new facility’s operating lease began August 11, 2017 and runs through August 2028.
- Management believed cash on hand at July 31 would fund operations through at least September 2018. Continuing beyond then depends on revenue growth and restrained expense increases; external financing may be needed. Failure to secure financing could require reductions, delays, or cancellation of activities. Equity financing could dilute shareholders; debt financing could add payment obligations and restrictive covenants.
- Stock-based compensation was $564,000, down from $1.129 million. A June 2017 extension of a former executive’s vested option terms generated a $56,529 modification expense.
- The filing reports no current legal proceedings and no accrued liquidated damages under a registration-rights arrangement; the company said it had filed the required registration statement and expected continued compliance. Related-party consulting payments included $18,000 to a director and $25,529 to a board member’s affiliate during the quarter.
Important facts for investors to verify
- Whether TOS bookings and revenue growth continue, and whether the reported margin improvement persists as study timing and costs change.
- Cash collections, deferred-revenue conversion, and the company’s ability to manage negative working capital and quarterly cash burn.
- Whether management’s September 2018 cash runway estimate remains achievable and whether additional capital will be required.
- Costs, utilization, and expected operating benefits of the new Rockville lab and its long-term lease commitment.
- Potential dilution from outstanding options and warrants; the filing lists 2.502 million options and 2.004 million warrants outstanding at July 31, 2017.